FMW Media's business TV show, New to The Street, announces signing
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) ("Acurx") to an
additional six-month media contract for filming and broadcasting
tailored interviews, commercials, and digital billboard ads.
New to The Street's TV anchors will continue
interviewing ACXP's management, discussing and introducing the
Company's key business topics. Each filmed interview will air on
New to The Street's televised syndicated outlets on Newsmax TV and
Fox Business Network and as a sponsored program on Bloomberg
TV.
Acurx Pharmaceuticals, Inc. is a clinical
biopharmaceutical business developing a new class of antibiotics
for bacterial infections. The Company's novel Ibezapolstat drug, a
potential treatment for Clostridioides difficile Infections (CDI),
completed FDA clinical results in Phase 1 and 2a and is currently
enrolling patients for an FDA Phase 2b clinical trial. CDI kills
thousands of people annually, with many catching the infection in
hospitals and nursing homes. Clinical data to date demonstrated
that Ibezapolstat eradicated CDI during 3-days of treatment.
The New to The Street's social media team and
television network partners will re-share media content, creating a
platform to increase awareness about Acurx. All broadcasted shows
will stream on the New to The Street website,
www.newtothestreet.com. On a schedule, show previews and commercial
ads will air on selected New to The Street syndicated and sponsored
TV platforms. Digital ads will stream on New to The Street's
billboard platform throughout New York City. And New to The Street
will provide social media marketing to further the reach of each
broadcast airing.
David Luci, the President / CEO of Acurx
Pharmaceuticals, Inc., states, "The previously aired interviews
that we did on New to The Street provided a fantastic platform for
Acrux to explain and educate viewers about our biopharmaceutical
business. As a publicly traded entity on the Nasdaq Capital Market
under the symbol NASDAQ: ACXP, we see New to The Street as a
perfect media platform to get information out to many, including
investors, about our operations and pipeline of drugs. I look
forward to continuing with the professional media experts at New to
The Street."
TV viewers will learn more about Acurx and get
updates as they become available regarding its new class of
antibiotics to combat CDI and other bacterial infections.
Vince Caruso, CEO / Producer of New to The Street,
states, "Our world is full of fear since the Covid outbreak, and
anything that has to do with bacterial infections concerns many.
Acrux Pharmaceuticals, Inc., with its pipeline of drugs, seeks
cures for some of the deadliest bacteria, and having them continue
the show is exciting for our viewers and us. As the Company
proceeds with its FDA Phase 2b clinical trials with its novel
Ibezapolstat drug for CDI, we anticipate great interviews and
updates from ACXP's management."
New to The Street's TV interviews with Acurx
Pharmaceuticals, Inc.'s management, airing on Newsmax TV
(syndicated), Fox Business Network (syndicated), and Bloomberg TV
(sponsored), "To Be Announced."
About Acurx Pharmaceuticals, Inc.
(NASDAQ: ACXP) ($ACXP):
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP)
($ACXP) is a clinical-stage
biopharmaceutical Company focused on developing new
antibiotics for difficult-to-treat infections. The Company's
approach is to develop antibiotic candidates that target the DNA
polymerase IIIC enzyme. Its R&D pipeline includes antibiotic
product candidates that target Gram-positive bacteria, including
Clostridioides difficile, methicillin-resistant Staphylococcus
aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and
drug-resistant Streptococcus pneumoniae (DRSP). The Company's
Ibezapolstat is a novel, orally administered antibiotic developed
as a Gram-Positive Selective Spectrum (GPSS™) antibacterial.
It is the first of a new class of DNA polymerase IIIC inhibitors
under development by Acurx to treat bacterial infections.
Ibezapolstat's unique spectrum of activity, which includes C.
difficile but spares other Firmicutes and the important
Actinobacteria phyla, appears to contribute to maintaining a
healthy gut microbiome. The Company completed Phase 1 and Phase 2a
clinical trials of ibezapolstat. To learn more about Acurx
Pharmaceuticals and its product pipeline, please
visit www.acurxpharma.com.
About New to The
Street:
New to the Street is an FMW Media production that
operates one of the longest-running US and International sponsored
and syndicated Nielsen Rated programming television brands, "New to
The Street," and its blockchain show, "Exploring The Block." Since
2009, these brands have run biographical interview segment shows
across major U.S. television networks. The paid-for-television
programming platforms can potentially reach over 540 million homes
in the US and international markets. FMW's New to The Street /
Newsmax televised broadcasting platform airs its syndication on
Saturdays at 3:30 – 4:00 PM ET. FMW is also one of the nation's
largest buyers of linear television, long and short-form paid
programming -
https://www.newsmaxtv.com/Shows/New-to-the-Street & https://www.newtothestreet.com/.
Forward-Looking Statements
Disclaimer:
This press release contains forward-looking
statements within Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934. In
some cases, you can identify forward-looking statements by the
following words: "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "ongoing," "plan,"
"potential," "predict," "project," "should," "will," "would," or
the negative of these terms or other comparable terminology.
However, not all forward-looking statements contain these words.
Forward-looking statements are not a guarantee of future
performance or results and will not necessarily be accurate
indications of the times at which such performance or results are
achieved. No information in this press release should be construed
as any indication whatsoever of the Company's future revenues,
results of operations, or stock prices. This press release should
be considered in all filings of the Companies contained in the
Edgar Archives of the Securities and Exchange Commission at
www.sec.gov. CONTACT:
FMW Media Contacts:
Monica Brennan monica@NewtoTheStreet.com
1-917-330-2564
"New to The Street" Business Development Office
1-516-696-5900 Support@NewtoTheStreet.com
Acurx Pharmaceuticals, Inc. David P. Luci,
President & CEO Tel: 917-533-1469
Email: davidluci@acurxpharma.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/251055dc-b9f5-40f5-ab64-0f969494694e
Acurx Pharmaceuticals (NASDAQ:ACXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acurx Pharmaceuticals (NASDAQ:ACXP)
Historical Stock Chart
From Apr 2023 to Apr 2024